

## Topical Collection

# New Insights in the Genetics and Genomics of Adrenocortical Tumors and Pheochromocytomas

### Message from the Collection Editor

Adrenal tumors are common and are often incidentally discovered during imaging (adrenal incidentalomas). Most of the adrenal tumors are indolent hormonally inactive tumors of adrenocortical origin, but hormonally active adrenocortical tumors, catecholamine-secreting adrenomedullary pheochromocytomas, and adrenocortical cancer have significant morbidity and mortality. Pheochromocytomas are rare, but exceptional, as germ-line genetic mutations are found in approximately 40% of cases that render pheochromocytomas the human tumors with the highest heritability. Several novel genes and pathomechanisms have been established in recent years in their pathogenesis. Genetic and genomics issues have relevance in the pathogenesis, diagnosis and treatment of these intriguing tumor types. This Topical Collection aims to cover several aspects of both adrenocortical cancer and pheochromocytomas involving advances in both genetics and epi/genomics.

---

### Collection Editor

Prof. Dr. Peter Igaz

Department of Endocrinology at the Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary

---



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/112458](https://mdpi.com/si/112458)

*Cancers*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)